Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Review Of Caremark Deal Will Be Fourth Look At PCS

Executive Summary

FTC's review of the Caremark/AdvancePCS merger will be the agency's fourth look at the PCS pharmacy benefit management business in less than a decade - but the first time the agency has considered a straightforward horizontal merger among independent, stand-alone PBMs

You may also be interested in...



Medco Eyeing “Vigorous” Public Relations Defense To False Claims Act Suit

Medco is planning an aggressive public relations defense to coincide with its legal fight against Philadelphia's U.S. Attorney

Medco Eyeing “Vigorous” Public Relations Defense To False Claims Act Suit

Medco is planning an aggressive public relations defense to coincide with its legal fight against Philadelphia's U.S. Attorney

Caremark/AdvancePCS Merger Will Give Company Half Medco’s Mail Capacity

Caremark will have about half of Medco's mail-order prescription capacity following the proposed acquisition of AdvancePCS

Related Content

UsernamePublicRestriction

Register

PS042423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel